At a glance
ClinicalIndex Comparison RecordN/ACompleted· 65 enrolled
Drug / intervention
Omalizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Omalizumab on Food Allergy in Children With Severe Asthma: A Real Life Study
In Brief
An observational study evaluating Omalizumab for Food; Allergy, Anaphylactic Shock and Asthma in Children. Completed, enrolled 65 participants across 1 site.
Detailed Summary
A prospective assessment of the impact of Omalizumab in terms of efficacy, safety, and quality of life (FA-QoL) in patients with moderate/severe asthma and history of anaphylaxis to peanut, tree nuts, fish, egg, milk, and/or wheat. Evaluation of the trend of total and specific IgE during Omalizumab treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
Primary CompletionMar 2023
First PostedMar 2024
TodayJul 2026
First PostedMar 18, 2024
Enrollment StartJan 1, 2018
Primary CompletionMar 31, 2023
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 2.3 years ago
Interventions
Omalizumabbiological
Administration of Omalizumab at the doses indicated for asthma in the EMA information leaflet.